帕唑帕尼在卵巢癌铂耐药复发后维持治疗中的疗效和安全性评价  

Efficacy and Safety Evaluation of Pazopanib in Maintenance Therapy after Platinum-resistant Recurrence of Ovarian Cancer

作　　者：刘玉梅 段瑞岐 LIU Yumei;DUAN Ruiqi(Department of Gynecology,Sichuan Friendship Hospital,Chengdu Sichuan 610066,China;Department of Obstetrics and Gynecology,West China Second Hospital,Sichuan University,Chengdu Sichuan 610041,China)

机构地区：[1]四川友谊医院妇科,四川成都610066 [2]四川大学华西第二医院妇产科,四川成都610041

出　　处：《实用妇产科杂志》2025年第3期259-262,共4页Journal of Practical Obstetrics and Gynecology

基　　金：成都市医学科研项目(编号:2024654)。

摘　　要：目的:探讨帕唑帕尼在卵巢癌铂耐药复发后维持治疗中的临床效果及安全性。方法:选择2018年1月至2024年1月于四川友谊医院就诊的卵巢癌铂耐药复发患者80例为研究对象。所有患者给予紫杉醇或吉西他滨单药化疗6~8个周期,待患者病情达到完全缓解(CR)或部分缓解(PR)后进入维持治疗,按简单随机法分为研究组(38例)和对照组(42例)。研究组给予帕唑帕尼维持治疗,对照组口服复方斑蝥胶囊维持治疗,两组治疗时间持续至病情进展为止。比较两组疾病无进展生存期(PFS)、血清癌抗原125(CA 125)水平、1年生存率以及药物不良反应发生情况。结果:研究组PFS(12.26±6.41月vs.6.29±4.53月)和1年生存率(71.05%vs.42.85%)均高于对照组,差异有统计学意义(P<0.05);研究组维持治疗3月后及肿瘤再次复发时的血清CA 125水平均低于对照组,差异有统计学意义(P<0.05)。研究组患者药物不良反应总体发生率高于对照组(52.63%vs.21.42%,P<0.05),主要为慢性腹泻、毛发及皮肤改变(包括脱发、头发变白、皮肤色素减退)。结论:在卵巢癌铂耐药患者复发后维持治疗中,口服帕唑帕尼可有效延长患者的疾病无进展期,且不良反应小、安全性高、患者依从性强。Objective:To evaluate the clinical efficacy and safety of Pazopanib in maintenance therapy after platinum-resistant recurrence of ovarian cancer.Methods:A total of 80 patients with platinum-resistant recurrence of ovarian cancer treated in Sichuan Friendship Hospital from January 2018 to January 2024 were selected as the study objects.All patients were given paclitaxel or gemcitabine monotherapy for 6-8 cycles and entered maintenance therapy after the patients achieved complete response(CR)or partial response(PR).They were divided into a study group(38 cases)and a control group(42 cases)using a simple randomization method.The study group was given pazopanib maintenance treatment,and the control group was given compound cantharides capsule maintenance treatment.The treatment time lasted until the disease progressed.Progression-free survival(PFS),serum CA 125 level,1-year survival rate,and adverse drug reactions were compared between the two groups.Results:Compared with the control group,PFS(12.84±6.23 months vs.6.12±4.82 months)and 1-year survival rate(73.68%vs.45.24%)in the study group were higher than those in the control group,the difference was statistically significant(P<0.05).The serum CA 125 level of the study group was lower than that of the control group after 3 months of maintenance treatment and when the tumor recurred again,and the difference was statistically significant(P<0.05).The overall incidence of adverse drug reactions in the study group was higher than that in the control group(52.63%vs.21.42%,P<0.05),but mainly chronic diarrhea,hair loss and hypopigmentation.Conclusions:In the maintenance treatment after recurrence of platinum-resistant patients with ovarian cancer,oral pazopanib can effectively prolong the disease progression-free period of patients with few side effects,high safety,and strong patient compliance.

关 键 词：帕唑帕尼 卵巢癌 铂耐药 复发 疾病无进展生存期 

分 类 号：R737.31[医药卫生—肿瘤]